Small Molecules

11 Jun 2017 Merck and Pfizer Announce that Investigational SGLT-2 Inhibitor Ertugliflozin Met Primary Endpoint in Two Phase 3 Studies
11 Jun 2017 Lexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 inTandem3 Study For Sotagliflozin In Patients With Type 1 Diabetes
11 Jun 2017 FDA requests removal of Opana ER for risks related to abuse
11 Jun 2017 NewLink Genetics to Regain Rights to GDC-0919
08 Jun 2017 Karyopharm Doses First Patient in Pivotal Phase 3 BOSTON Study Evaluating Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
08 Jun 2017 Actelion provides an update on the Phase III IMPACT program with cadazolid in CDAD
07 Jun 2017 Spring Bank Provides Update on its Next-Generation STING Platform and Announces Publication of an Abstract at ASCO Related to its Lead STING Agonist Candidate, SB 11285
07 Jun 2017 InCarda Therapeutics Announces Positive Clinical Data Supporting Development of Inhaled Flecainide for the Treatment of Symptomatic Acute Events of Paroxysmal Atrial Fibrillation (PAF)
07 Jun 2017 Avanir Pharmaceuticals Initiates Phase II Study to Evaluate AVP-786 for Treatment of Neurobehavioral Disinhibition Associated with Traumatic Brain Injury
07 Jun 2017 Entasis Therapeutics Presents Data on Third Drug Candidate, ETX0282, an Orally Available, Extended-Spectrum Βeta-lactamase Inhibitor, at ASM Microbe 2017
07 Jun 2017 ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases
07 Jun 2017 AbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Phase 3 Study in Rheumatoid Arthritis
07 Jun 2017 NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell Culture Studies
07 Jun 2017 Jazz Pharmaceuticals Presents Data for the Phase 3 TONES 2 Study of JZP-110 in Patients with Excessive Sleepiness Associated with Narcolepsy
07 Jun 2017 Oragenics Presents Development of Novel Lantibiotic Against Clostridium difficile at the ICAAC Conference
07 Jun 2017 CVT-301 Phase 3 Data Showed Significantly Improved Motor Function During OFF Periods in Parkinson’s Disease
06 Jun 2017 Exploratory Analysis of the Phase I/II CHRYSALIS Study of gilteritinib Demonstrates First Molecular Response to FLT3 Inhibitor in Acute Myeloid Leukemia
06 Jun 2017 Updated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation
06 Jun 2017 Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients
06 Jun 2017 Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2a Clinical Trial
06 Jun 2017 Viking Therapeutics Announces Promising Top Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)
06 Jun 2017 FDA Approves Two-Month ARISTADA® for Treatment of Schizophrenia
06 Jun 2017 Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting
06 Jun 2017 Boston Biomedical Presents Data for Investigational Stemness Inhibitor Amcasertib at ASCO 2017
06 Jun 2017 ESSA Pharma Presents Data From Phase 1 Trial of EPI-506 at 2017 ASCO Annual Meeting

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top